THE FIRST AND ONLY PPI WITH A DUAL DELAYED RELEASE (DDR) FORMULATION, WHICH PROVIDES A SECOND RELEASE OF DRUG
DEXILANT is the first and only PPI with a Dual Delayed Release (DDR) formulation, which results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1–2 hours after administration, followed by a second peak within 4–5 hours.1
Conclusions of comparative efficacy cannot be drawn from this information.
See About DEXILANT for more information on how the Dual Delayed Release (DDR) formulation works.
DEXILANT IS EFFECTIVE IN THE TREATMENT OF GERD, CAN BE TAKEN WITHOUT REGARD TO FOOD, AND OFFERS A SAFETY AND TOLERABILITY PROFILE SIMILAR TO LANSOPRAZOLE
DEXILANT 60 mg provided consistently high EE healing rates at week 8.1 DEXILANT 30 mg provided full 24-hour heartburn relief in a majority of symptomatic non-erosive GERD patients at week 4.1 Clinical studies have shown that DEXILANT offers a safety and tolerability profile similar to lansoprazole.1 And DEXILANT can be taken without regard to food.1
- DEXILANT should be swallowed whole. Alternatively, capsules can be opened, sprinkled on 1 tablespoon of applesauce, and swallowed immediately. Granules should not be chewed. Do not store for later use.
- While DEXILANT can be taken without regard to food, some patients may benefit from administering the dose prior to a meal if post-meal symptoms do not resolve under post-fed conditions
- DEXILANT 30 mg should be considered for patients with moderate hepatic impairment
For more details, please see the full Prescribing Information.
Reference: 1. DEXILANT (dexlansoprazole) package insert, Takeda Pharmaceuticals America, Inc.
DEXILANT is indicated for:
- Healing all grades of erosive esophagitis (EE) for up to 8 weeks
- Maintaining healing of EE and relief of heartburn for up to 6 months
- Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Important Safety Information
- DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use.
- Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy.
- Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
- Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
- Most commonly reported adverse reactions were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
- Do not co-administer atazanavir with DEXILANT because atazanavir systemic concentrations may be substantially decreased. DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.
Please see the full Prescribing Information for DEXILANT.
This site is intended for US residents only